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Recent information obtained, mainly by recombinant cDNA technology, on structural heterogeneity of 
hormone and transmitter receptors, of GTP-binding proteins (G-proteins) and, especially, of G-protein-linked 
receptors is reviewed and the implications of structural heterogeneity for diversity of hormone and transmitter 
actions is discussed. For the future, three-dimensional structural analysis of membrane proteins participating in 
signal transmission and transduction pathways is needed in order to understand the molecular basis of allosteric 
regulatory mechanisms governing the interactions between these proteins including hysteretic properties and cell- 
cybernetic aspects. 
Thanks to recombinant DNA technology, there has been 
a recent flood of structural information on membrane recep- 
tors, G-proteins and target enzymes [for reviews see Gilman 
(1987), Casey and Gilman (1988), Lefkowitz and Caron 
(1988), Levitzki (1988), Neer and Clapham (1988), Pfeuffer 
and Helmreich (1988), Freissmuth et al. (1989), Gilman 
(1989), Birnbaumer et al. (1989), Strader et al. (1989), 
Birnbaumer (1990), Birnbaumer et al. (1990)l. This work 
brought to light not only a high degree of structural heterogen- 
eity but also interesting structural relationships. 
The consequences of the extensive structural heterogeneity 
among the proteins involved in signal transmission are far- 
reaching. Accordingly, this review deals mainly with the impli- 
cations of structural heterogeneity, mainly of G-proteins and 
G-protein-linked receptors, for the diversity and multiplicity 
of signal transmission and cellular regulation mechanisms. 
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strasse 2, W-8700 Wiirzburg, Federal Republic of Germany 
Abhreviutions. AcCh, acetylcholine; nAcChR, nicotinic acetyl- 
choline receptor; GABAA, receptor which binds y-aminobutyric acid 
(GABA). [Purinergic (P) ligands ATP, ADP, AMP and adenosine, 
cf. Burnstock, 1978; Burnstock and Kennedy, 19851; G-proteins, 
heterotrimeric GTP-binding proteins composed of LY-, B- and y-sub- 
units; G,, stimulatory G-protein; Gi, inhibitory G-protein; Go, brdin- 
derived G-protein; G, (transducin), rhodopsin-linked G-protein etc.; 
ras, rho, etc., small monomeric G-proteins; GAP-43, growth-associ- 
ated protein with M ,  43000; ARF, ADP-ribosylating factor; GAP, 
GTPase-activating protein; GEF, GDP-exchange factor; GTP[yS], 
guanosine 5’-0-(3-thiotriphosphate); PtdIns, phosphatidyl 1-inositol; 
MDCK cells, Madin-Darby canine kidney cells; GH,C1, pituitary 
cell line from the rat; BALB-c-3T3 cells are from a mouse fibroblast 
cell line; carazolol, 1-(9H-carbazol-4-yloxy)-3-[(l-methylethyl)- 
amino]-2-propanol is a j-adrenergic blocker; CGP-12177 is a P-adren- 
ergic antagonist and the Ciba Geigy product 12177, 4-[3-(t-butyl- 
amino)-2-hydroxypropoxy]benz-imidazol-2-on. 
The selection of examples to support the arguments advanced 
in this review is quite arbitrary and is heavily biased towards 
the P-adrenoceptorlG-proteinladenylate cyclase. In addition, 
some regulatory properties of the acetylcholine receptor are 
also discussed. The reasons for this bias are to be found in the 
research interests of the authors. For the reader interested in 
additional and more detailed information regards the topic 
under discussion, recent reviews by Birnbaumer et al. (1990) 
and Bourne et al. (1990) are recommended. 
Structural properties of membrane receptors 
Many hormones, neurotransmitters and growth factors 
act as extracellular signals which bind first to receptors at the 
cell membrane surface. In this context, we shall restrict our 
discussion to plasma membrane receptors and signal transduc- 
tion mechanisms originating from them and will not consider 
steroid hormones. The receptors we are dealing with are trans- 
membranous glycoproteins. On binding a hormone, a 
neurotransmitter or any agonist, the receptor is activated in a 
manner which is not yet understood at the molecular level; 
the phenomenological consequences of activation are better 
known. Pharmacologists have classified receptors according 
to the ligands which they bind (Ahlquist, 1948). Accordingly, 
one has to distinguish between adrenergic, cholinergic, hista- 
minergic, dopaminergic receptors, and so forth. Tacitly, it was 
implied that a receptor activated by an agonist of a given class 
initiates a sequel of biological events which are unique for 
this type of ligand. However, newer evidence suggests that 
different receptors may have similar actions and conversely a 
given receptor class can have multiple functions (see Fig. l), 
thus casting doubts on the validity of the above classification. 
But in the future, the structural information already available 
and still forthcoming could serve as a basis for a new classifi- 
cation scheme. 
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Fig. 1. Multiplicity of receptor- G-protein - target activation. A simi- 
lar diagram of the information flow through G-protein-coupled signal 
transduction pathways has been presented by Birnbaumer et al. (1989, 
1990) 
Based on their structures, membranous proteins, including 
membrane receptors, can already be divided in two main 
classes: receptors where the polypeptide chains span the 
membrane only once and receptor polypeptides which span 
the membrane several times. To the first group belong recep- 
tors with intrinsic tyrosine kinase activity, such as the receptors 
for insulin (see Olson and Lane, 1989), insulin-like growth 
factors, epidermal growth factor, platelet-derived growth 
factor and others. The second group comprises the super- 
family of the 'ligand-gated' ion channels including the nic- 
otinic acetylcholine receptor (nAcChR; see Stroud et al., 1990) 
and the y-aminobutyric acid (GABA) receptors (see Schofield 
et al., 1987) and all receptors whose actions are amplified by 
GTP-binding proteins. Receptors expressing tyrosine kinase 
activity bind polypeptide hormones and growth factors. 
There is considerable evidence that, in the case of receptors 
with tyrosine kinase activity, activation on binding of an ap- 
propriate ligand initiates aggregation (for reviews see Czech, 
1985, and Boni-Schnetzeler et al., 1986). For example, EGF 
induces receptor oligomerization and triggers auto-phos- 
phorylation (Zidovetzki et al., 1981 ; Schlessinger, 1986; 
Cochet et al., 1988). Receptor oligomerization has also been 
observed with other peptide binding receptors (cf. Brenner et 
al., 1985; Sharon et al., 1986) and in the case of ion-channel- 
forming receptors (Schofield et al., 1987). 
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Fig. 2. Crosslinking of turkey erythrocyte B1-udrenoceptors. (Based on 
unpublished experiments of Boege 1990.) Turkey erythrocyte mem- 
branes were treated with bis(sulfosuccinimidy1)suberate according to 
Staros (1982). For that purpose, 0.6 mg/ml membrane protein was 
incubated with 50 FM bis(sulfosuccinimidy1)suberate in 50 mM 
Hepes pH 7.5, 200 mM NaCl and 30 mM MgClz for 1 h at room 
temperature. The reaction was terminated by addition of 0.1 vol. 
500 mM Tris/HCl pH 7.5. 8,-Adrenoceptors in the membrane prep- 
arations were tagged radioactively by treatment with the photoaffinity 
reagent, [' 25]iodocyanopindolol-azide-2 ( .2 pCi/mmol), synthesized 
and applied as described by Burgermeister et al. (1982). After com- 
pletion of the reaction, the membrane proteins were analyzed by SDS/ 
PAGE under non-reducing conditions in 4- 12% polyacrylamide 
gradient gels. Rabbit skeletal muscle myosin ( M ,  200000), rab- 
bit skeletal muscle phosphorylase h ( M ,  = 97000), ovalbumin 
( M ,  = 43000) and carbonic anhydrase ( M ,  x 30000) were used as 
M ,  markers. Lanes I ,  control, not activated or crosslinked; lanes 2, 
crosslinked; lanes 3, activated with 1 pM I(-)isoproterenol for 1 h at 
30"C, not crosslinked; lanes 4, activated as in lane 3 followed by 
crosslinking as in lane 2; (+) nonspecific incorporation of the 
photoaffinity label remaining after blockade of the receptor with 
20 pM CGP 12177, a 8-receptor-specific antagonist 
Regarding P-adrenoceptors in intact cells in tissue culture, 
a patched non-homogeneous distribution in the plasma mem- 
brane was observed in a temperature range of 4-37°C using 
the technique of fluorescence recovery after photobleaching 
(Henis et al., 1982). In addition, Fraser et al. (1987) have 
detected in the course of purification of /?-adrenoceptors small 
amounts of receptor dimers and tetramers. 
We have studied aggregation of P,-adrenoceptors in turkey 
erythrocyte membranes (F. Boege, unpublished experiments, 
1990) using bis(sulfosuccinimidy1)suberate as crosslinking re- 
agent. The same reagent was used to crosslink EGF-receptor 
dimers (Fanger et al., 1989). But, in contrast to the EGF 
receptor, the /?,-adrenoceptor from turkey erythrocytes did 
not form dimers or oligomers on hormone binding and acti- 
vation. As demonstrated in Fig. 2, a small amount of the pl- 
receptor appears to be preaggregated in the absence of ligand. 
However, stimulation by the agonist did not alter the quar- 
ternary structure of the /?,-adrenoceptor and neither did 
crosslinking of the activated receptor trap aggregated forms of 
the receptor, whereas, under comparable conditions, spectrin 
dimers were crosslinked with great efficiency. Even consider- 
ing that some of the /?,-receptors may not have reacted with 
the crosslinking reagent, it seems highly unlikely on the basis 
of these experiments that receptor aggregation plays a major 
role in activation of /?,-adrenoceptors by catecholamines. 
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In the case of the insulin receptor, phosphorylation sites 
are on the carboxy-terminal part of the P-chain; autophos- 
phorylation is thought to activate the tyrosine kinase and to 
result in phosphorylation of substrate proteins, among which 
could be a serine-threonine-specific protein kinase (or protein 
phosphatase) which could trigger a whole complex phos- 
phorylation-dephosphorylation cascade (Czech et al., 1988). 
At present, however, it is not clear on a molecular level how 
autophosphorylation activates the receptor-associated tyro- 
sine kinase, nor can one say whether a phosphorylation cas- 
cade initiated by tyrosine phosphorylation is the only, or even 
the major, mechanism of signal transduction by this kind of 
receptor. For example, a participation of G-proteins in the 
action of insulin and epidermal growth factor has been in- 
voked (cf. Heyworth et al., 1985; Ciaraldi and Maisel, 1989; 
Kelvin et al., 1989; Nair et al., 1989). 
The structure of the receptors which span the membrane 
more than once has been modelled in analogy to the structure 
of bacteriorhodopsin, although a high-resolution three-di- 
mensional structure of any one receptor of this kind has not 
yet been forthcoming. Bacteriorhodopsin belongs to a class 
of halobacterial retinal-binding proteins which can utilize light 
energy to drive an ATP-generating proton pump. This class 
of membrane proteins, to which among others also belong 
the /I-adrenoceptors and rhodopsin in the rod outer segment 
membranes of the retina, is assumed to have seven membrane- 
spanning domains. One should be aware, however, that in the 
absence of a three-dimensional structure, structural details 
based on the model with seven membrane-spanning domains 
must remain conjectural for any receptor (see Lodish, 1988; 
Hartmann et al., 1989). It is mainly based on hydrophilicity/ 
hydrophobicity profiles and the accessibility of the receptor 
in the membrane to protease digestion. 
In the case of bacteriorhodopsin, Henderson and Unwin 
(1 975) originally visualized, by low-energy electron diffrac- 
tion at 0.6-nm resolution, seven transmembrane @-helices. 
Henderson et al. (1990) have recently presented a refined 
structure at 0.35-nm resolution. In the case of the PI-, / 1 2 -  and 
al-adrenoceptors and for a similar protein, G21, which is 
a serotonin receptor subtype, a structure with seven highly 
conserved transmembraneous segments, each with 20 - 28 
hydrophobic amino acids linked by three external and three 
cytoplasmic loops, has been proposed (see Fig. 3). Cytoplas- 
mic loops C1 and C2, with the corresponding transmembra- 
nous domains and the outside loops, are conserved. The con- 
served regions on the outside and parts of the transmembra- 
nous domains are assumed to be crucial for ligand binding. 
This is mainly based on results from site-directed mutagenesis 
studies, deletion mutants and experiments with site-specific 
peptides (Dixon et al., 1987; Strader et al. 1987a, b, 1988; 
Cotecchia et al., 1988, 1990; Fargin et al., 1988; Hamm et al., 
1988; Kobilka et al., 1988; O’Dowd et al., 1988; Regan et al., 
1988; Fraser, 1989; Palm et al., 1989, 1990; Dohlman et al., 
1990). 
Heithier et al. (1988) have probed the environment of the 
ligand binding site with a fluorescent specific P-adrenergic 
antagonist which was environmentally sensitive. Tota and 
Strader (1990) have characterized the binding site of a hamster 
/l,-adrenergic receptor expressed in baculovirus-infected 
Spodoptera frugiperdu insect cells with the antagonist carazolol 
as fluorescent probe. However, the results obtained with 
the fluorescent and more hydrophilic CGP-12177 derivative 
(Heithier et al., 1988) and the hydrophobic carazolol (Tota 
and Strader, 1990) were quite opposite; whereas the latter 
sensed a very hydrophobic environment, a more hydrophilic 
binding site was detected by the former probe. The third, large 
cytoplasmic loop, C3, and the cytoplasmic carboxy-terminal 
part differ among the members of this receptor family and 
parts of these structures could therefore be responsible for 
receptor-specific interactions with G-proteins (for additional 
information see also Dixon et al., 1988; Lefkowitz and Caron, 
1988; Strader et al., 1989). 
The regions of the /l-adrcnoceptor important for G-protein 
coupling are the N- and C-terminal segments of the third 
intracellular loop (see Fig. 3). However, the primary sequences 
of these regions are divergent among G-protein-coupled re- 
ceptors. Cheung et al. (1989) and Huang et al. (1990) have 
suggested that a putative secondary structure motif of these 
regions, namely an amphipathic a-helical structure, which 
is conserved among all G-protein-coupled receptors whose 
sequences have been determined, is responsible for receptor - 
G-protein interaction. Polyanions, which inhibit receptor - 
G-protein coupling, are believed to interact with the largely 
cationic face of the putative amphipathic helix. 
All receptors which couple to G-proteins are glycoproteins 
with glycosylation sites at the N-termini and phosphorylation 
sites at the cytoplasmic carboxy terminal domain to which p- 
arrestin binds (see Boege et al., 1988; Lohse et al., 1990). The 
human Pz-adrenoceptor is also linked to a fatty acid, is has a 
palmitoyl residue (O’Dowd et al., 1989). Mutant receptor 
molecules in which cysteine 341 was replaced by glycine no 
longer have this residue and showed decreased activation of 
adenylate cyclase in response to isoproterenol. Since cysteine 
341 is conserved in every G-protein-coupled receptor exam- 
ined, all members of this receptor family might be 
palmitoylated. Acylation of cysteine 341 might be expected to 
promote binding of this region to the membrane, thus creating 
a fourth intracellular loop which is assumed also to be in- 
volved in G-protein binding, but how fatty acylation aids in 
the formation of a functional G-protein binding site is not 
known (James and Olson, 1990). 
The largest sequence similarity (54% ) is found between 
PI - and /l,-adrenoceptors. The overall sequence similarity is 
matched by similar binding properties towards a series of 
catecholamines. The muscarinic acetylcholine receptor sub- 
types MI and M2 are more distant on the basis of their 
primary structure (Lefkowitz and Caron, 1988). But despite 
the structural similarities, the separate genes for the p,- and 
@,-receptors, which have no introns, do not hybridize (Frielle 
et al., 1987). 
The number of members of this family of receptor genes 
is still growing: a 343-amino-acid-containing protein, named 
rat thoracic aorta protein, is a candidate for a G-protein- 
coupled receptor (Ross et al., 1990). A human (p,) adreno- 
ceptor was cloned and expressed in Escherichiu coli (Marullo 
et al., 1988) and a human p3-adrenoceptor was detected using 
the polymerase chain reaction (Emorine et al., 1989). One of 
the members of this adrenoceptor class is closely related to 
the serotonin receptor. Two other genes apparently code for 
a new subfamily of G-protein-coupled receptors which have 
very short non-glycosylated N-terminal additions. 
G-protein-coupled receptors are found at every level of 
the evolutionary scale. G-protein-linked receptors are highly 
adaptable with respect to both the chemical structure of the 
ligand which they accomodate and with respect to their func- 
tion. It now seems that several G-protein-linked neural recep- 
tors which are coupled to phospholipase C and catalyze 
phosphatidylinositol 4,5-bisphosphate hydrolysis, including 
the 5-hydroxytryptamine and the mas-oncogene-associated 
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Fig. 3. Hypothetical and highly schematic membrane topology of G-protein-linked receptors. The membrane orientation based on hydrophobicity 
indicates seven membrane-spanning helices joined by three extracellular (left side) and three cytoplasmic loops (right side) (see also Strader et 
al., 1989) 
angiotensin receptor, have mitogenic potentials. All the 
muscarinic receptors so far identified can apparently stimulate 
DNA synthesis. This suggests that receptors coupled to differ- 
ent signalling pathways, for example muscarinic acetylcholine 
receptors which also participate in the inhibitory control of 
adenylate cyclase through Gi, may also be involved in cell 
proliferation. 
Recent evidence points to possible connections between 
G-protein- and growth-factor-dependent mechanisms. Data 
obtained with mouse BALB-c-3T3 embryonic cells suggest 
cooperative effects on cell proliferation of classical G-protein- 
dependent signal pathways and of growth-factor-receptor-as- 
sociated tyrosine kinases (see Dumont et al., 1989; Kojima et 
al., 1989). Hanley (1989) has actually suggested, while dis- 
cussing these and other results, that all the important signal 
transduction pathways controlled by G-protein-coupled re- 
ceptors may be mitogenic. To this group belongs a number of 
receptors for functionally different hormones. Among them 
are receptors for catecholamines and cholinergic ligands and 
biogenic amines such as serotonin and dopamine, receptors 
for substances K (Masu et al., 1987) and P (Yokota et al., 1989) 
and luteinizing hormone (Loosfelt et al., 1989; McFarland et 
a]., 1989) as well as rhodopsin, the light receptor in visual 
signal transmission (Stryer, 1986) and the receptors for the 
mating factor of yeast (Dietzel and Kurjan, 1987; Herskowitz 
and Marsh, 1987) and for the chemotactic CAMP in 
Dictyostelium discoideum (van Haastert, 1987). This list is 
incomplete (see also Barnard, 1988; Boulay et al., 1990). 
Birnbaumer et al. (1990) have listed about 80 receptors acti- 
vated by G-proteins. In this review, the reader will find a more 
complete list of references. 
One major reason for the existence of the bewildering 
number of receptor subtypes based upon different DNA se- 
quences is tissue specialization. Some of the isoforms are also 
likely to be developmental specializations. But this is not the 
only reason for functional diversity. The adrenoceptor family 
is an example: K ~ - ,  K ~ - ,  PI- and Pz-adrenergic receptors are 
distinguished by the chemical specificity of their ligand bind- 
ing. However, this pharmacological classification tells us little 
about the biological function: a l -  and cr,-receptor subtypes 
and probably also P-adrenoceptors can have multiple and 
diverse functions: functional diversity may be due to the Fact 
that each receptor subtype couples to a different G-protein or 
it may depend on whether one receptor couples with more 
than one distinct G-protein (Fig. 1 C). A less likely possibility 
would be that one given G-protein interacts with more than 
one cellular target (Fig. 1 B). 
The group of transmembrane receptors which span the 
membrane several times also includes the ligand-gated ion 
channels. Functionally, these membrane glycoproteins are hy- 
brids between receptors and effectors: they are receptor chan- 
nels. To this group belongs the nicotinic acetylcholine receptor 
which functions as a channel for monovalent cations (Changeux 
et al., 1984). We also include in this group the receptor for 
inositol trisphosphate because it is a Caz+ channel in the 
endoplasmic reticulum. In this case, the ligand is not a hor- 
mone or neurotransmitter but a second messenger (Berridge 
and Irvine, 1989). Studies from several laboratories (Supat- 
tapone et al., 1988; Ferris et al., 1989; Furuichi et al., 1989) 
have indicated that the structure of the inositol trisphosphate 
receptor is strikingly similar to the recently cloned CaZt chan- 
nel of the sarcoplasmic reticulum of skeletal muscle which 
binds ryonidine. This was recently discussed by Gill (1989). 
From hydrophobicity profiles, it was concluded that the pro- 
tein may contain between seven and nine membrane-spanning 
domains. The cDNA-derived M ,  is 313000 but the M ,  of 
the solubilized protein is around lo6, suggesting a tetrameric 
structure. Cooperativity of inositol trisphosphate binding is 
in accordance with an oligomeric structure. In a model, it is 
assumed that four subunits surround a central Ca2 + channel. 
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Fig. 4. Hypothetical membrane topology of the GABA receptor ,from 
bovine cerebral cortex. [Reproduced from Schofield et al. (1987) with 
permission of the author and Nature.] This schematic model is rep- 
resentative for a receptor family to which also the nicotinic 
acetylcholine and the glycine receptors belong. The cylinders represent 
four membrane-spanning helices in each subunit. It is assumed that 
two copies of each of the subunits are present in the E- and /?-receptor 
complexes. The charged residues (@, e) are indicated. The site for 
CAMP-dependent serine phosphorylation in the /?-subunit is marked 
(P) and the extracellular sites for N-glycosylation are indicated by (V) 
In cases where a receptor has an oligomeric structure, as 
exemplified by the nicotinic acetylcholine receptor (a2jyS), 
the possibilities for structural heterogeneity will become even 
more numerous. When, for example, subtypes of each mono- 
mer exist, a large number of variations is possible in the 
arrangement of oligomers. An impressive recent example of 
that kind of structural variability is the GABAA receptor 
which is also a chloride channel (Schofield et al., 1987; see 
Fig. 4). This receptor binds the inhibitory neurotransmitter y- 
aminobutyric acid (GABA). It is a hetero-oligomeric protein 
made up from subunits of which each contains four mem- 
brane-spanning helices. The polypeptides have only 20 - 40% 
identity with each other and 10-20% identity with the poly- 
peptides of the nAcCh receptor and of the strychnine-sensitive 
glycine receptor. Since each polypeptide is coded by several 
genes, a number of heterogenous forms with 60-80% se- 
quence similarity may be expressed. Different subtypes, then, 
give rise to a variety of different oligomeric isoforms with 
different pharmacological sensitivities. On the other hand, 
heterogeneity resulting from variations in the level of ex- 
pression and post-translational modification may be respon- 
sible for regional differences in the function of GABAA recep- 
tors in the brain (Olsen and Tobin 1990). 
Among the dozens of receptors which couple with G- 
proteins and activate adenylate cyclase, both PI- and P2- 
adrenoceptors have been cloned and purified to homogeneity 
(for the original literature see Lefkowitz and Caron, 1988) 
and reconstituted functionally in lipid vesicles together with 
purified G-proteins and the target enzyme, adenylate cyclase 
(May et al., 1985; Feder et al., 1986). Actually, P-adrenergic 
activation of adenylate cyclase is the signal transmission path- 
way which, together with visual signal transmission in the 
retina, has been studied in greatest detail (for reviews see 
Lefkowitz and Caron, 1988; Levitzki, 1988; Pfeuffer and 
Helmreich, 1988). 
Catecholamines, adrenaline, noradrenaline and many syn- 
thetic adrenergic agonists, partial agonists and blockers bind 
to adrenoceptors. Analysis at the level of the gene has iden- 
tified the structural domains involved in ligand binding. The 
replacement of single highly conserved cysteinyl residues 
either in a transmembrane domain or in a cytoplasmic domain 
led either to an unchanged or an increased ligand affinity 
but in each case resulted in a significant impairment of the 
receptor’s capacity to stimulate adenylate cyclase (Fraser, 
1989; O’Dowd et al., 1989; Hausdorff et al., 1990b). In sup- 
port of the importance of cysteinyl residues in fl-adrenoceptor 
function are recent data on a role of disulfide bridges in 
forming the ligand binding site of the P,-adrenergic receptor 
(Dohlman et al., 1990). The use of site-directed mutagenesis 
helped to clarify the involvement of disulfide bonds in ligand 
binding to the /3-receptor; the evidence presented in previous 
studies gave equivocal results because they were carried out 
with crude receptor preparations or membranes and with re- 
ducing agents, dithiothreitol, or sulfhydryl-specific agents, 
such as N-ethylmaleimide, so that effects on other components 
of the adenylate cyclase system could not be excluded (see 
Vauquelin et al., 1979; Heidenreich et al., 1982; Korner et al., 
1982). Therefore, sulfhydryl - disulfide interchange may also 
play a role in the activation of P-adrenoceptors (Moxham et 
a]., 1988) as it does in the case of insulin receptors (cf. Olson 
and Lane, 1989; see also Fig. 5) .  
Various /I-adrenergic agonists differ in affinity to p- 
adrenoceptors but increased efficacy is not necessarily associ- 
ated with increased affinity (Eimerl et al., 1987). Moreover, 
one and the same ligand can act as antagonist, partial agonist 
or full agonist depending on the cellular medium, as shown 
with CGP 121 77, a hydrophilic j-adrenergic ligand originally 
thought to be an antagonist (Staehelin et al., 1983; Portenier 
et al., 1984; Mohell and Dicker, 1989). Finally it must be said 
that the influence of the membraneous environment on the 
efficacy of hormones and agonists has been neglected. But as 
long as the molecular mechanisms of receptor activation are 
unknown, it will remain difficult to explain functional hetero- 
geneity of receptors as a result of environmental effects, as 
exemplified by the case of vasoconstrictive a,-adrenoceptors 
which vary in different tissues and in different animal species 
in ligand affinity and biological activity (Bevan et al., 1989). 
What applies to p-adrenoceptor activation also applies to 
desensitization (Hausdorff et al., 1990a; see Fig. 5). There- 
fore, at present the non-responsiveness of receptors to agonists 
can only be described phenomenologically, since information 
on the nature of structural transitions accompanying acti- 
vation and deactivation is not yet available. As an example, 
the phenomenon of hysteretic behavior in response to agonist 
binding to the nAcChR will be described. 
Receptor desensitization and membrane transduction hysteresis 
In the case of enzymes, kinetic delay phenomena, resulting 
from binding of substrate or other kinds of ligands, are some- 
times denoted as hysteretic behaviour (Frieden, 1971). This 
concept was applied to adenylate cyclase and the activation 
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Fig. 5.  Events in activation and desensitization of p-adrenoceptor func- 
tion 
of G, by Mg2+ ions (Iyengar, 1981). In the case of the nAcChR 
of Torpedo calijornica electrocytes, an extremely stable hyster- 
esis loop exists in neurotransmitter binding due to a concen- 
tration-dilution cycle for the agonist (Chang et al., 1984). 
Antagonists, on the other hand, show conventional equilib- 
rium binding, but no hysteresis. The structural hysteresis with 
respect to acetylcholine (AcCh) binding was interpreted in 
terms of extremely long-lived metastable conformations of the 
receptor homodimer species (Mr 580 000). Phenomenologi- 
cally, the main hysteresis loop has internal smaller scanning 
loops (Fig. 6) and therefore, at a given AcCh concentration, 
the main loop can be transversed from the lower to the upper 
branch, for example on dialysis (Neumann et al., 1988). Hys- 
teresis is not only an indication for structural cooperativity in 
non-equilibrium states, but a hysteresis loop is also a physical 
memory device. Furthermore, hysteresis can be a mechanism 
leading to chemical oscillations. Along these lines the scanning 
curves of the nAcChR system can, in principle, function as a 
multidomain memory system (Neumann, 1973). 
AcChR hysteresis and receptor desensitization appear to 
be intimately related, because hysteresis is observed in a con- 
centration range where the receptor becomes desensitized. The 
receptor can exist in various interconvertible conformational 
states: Rh (high AcCh binding affinity, Kh % lo-’ M), Rvh 
(very high AcCh binding affinity, Kvh I M) (see Fig. 7), 
and a low-affinity state, RI, (K, ”N M) which is the chan- 
nel-active state. Accordingly, the capability of a protein to 
form long-lived metastable states with hysteretic properties is 
thought to allow a receptor to dampen activation and main- 
tain an inactive state. Hysteretic behaviour in activator bind- 
ing qualifies a receptor as a structure which recalls previous 
1 .o 
PA 0.5 
0 
Fig. 6. Hysteresis loop of acetylcholine ( A ) ,  binding to Torpedo 
californica nicotinic acetylcholine receptor (nAcChR) in membranes. 
On the ordinate, flA is the degree of binding of AcCh. At equilibrium, 
PA = [A]/([A] +a, where K is the overall equilibrium constant 
( 5  +_ 2 nM). On the abscissa is given the molar concentration of free 
A. (A) The lower branch of the hysteresis loop was obtained after a 
pulse-like addition of A; (0) the upper branch was obtained after 
equilibrium dialysis for 22 h at 4’C; it therefore represents the equilib- 
rium binding curve with K = 5 (f 2) nM, whereas the lower branch 
represents a distribution of long-lived metastable receptor conformers 
(see text). Dilution scans (0) are shown starting at B and C from the 
lower hysteresis branch represented by Q, the half-saturation value 
which was 0.04 (+_ 0.02) pM at 4°C. The receptor concentration based 
on M ,  = 290000 was always 1 KM. (m) Data points from experiments 
where the phosphatidylinositol-4-kinase activity of the isolated, 
purified receptor was measured as a function of [A]. For further 
details see Neumann et al. (1988) and text 
encounters with an agonist. For example, a small degree of 
binding is indicative for a pulse-like exposure to the agonist, 
whereas a high degree of binding points to a slow, leak-like 
exposure of low, diluted concentrations of AcCh to the recep- 
tor. 
It is commonly assumed that a desensitized receptor has 
lost its function. But recent evidence suggests that a des- 
ensitized nAcChR may not be completely nonfunctional; a 
desensitized receptor may no longer be capable of activating 
the primary response characteristic for the hormone or trans- 
mitter to which it binds, but it may still be capable of activating 
a secondary pathway more slowly. This was shown to be the 
case with the desensitized nAcChR of Torpedo. Both AcCh 
monomers and dimers, although the latter to a much greater 
extent, were found to catalyze the formation of 
phosphatidylinositol 4-phosphate (PtdIns4P) from receptor- 
associated phosphatidyl-inositol (PtdIns) and Mg2 +-ATP and 
also its hydrolysis (Kiehl et al., 1987; Herlemann, 1989). This 
catalytic activity of the Torpedo nAcChR is expressed in the 
same concentration range of AcCh in which channel-des- 
ensitization of the receptor occurs. A similar situation, that is 
a dual function of a receptor, was recently encountered in the 
case of glucagon and prostaglandin El-receptors on MDCK 
cells (Kurstjens et al., 1990a). Another interesting example is 
the stimulation of phospholipase C by (P) ligands in turkey 
erythrocyte membranes which was dependent on guanosine 
5’-0-(3-thiotriphosphate) (GTP[yS]) like the G-protein-de- 
pendent activation of adenylate cyclase in these cells (Boyer 
et al., 1989). In this case, the activation by GTP analoga was 
delayed, pointing to a kinetically ‘hysteretic’ activation. 
It should be noted that the PtdIns kinase activity of the 
Torpedo nAcChR in response to AcCh increased along the 
lower branch of the hysteresis loop (cf. Fig. 6). Since the extent 
of expression of the PtdIns kinase and PtdIns4P hydrolase 
7 
I' 
2 A +  Rh.Rh + ARh.Rh + A + A R h . A R h  
4 11 
11 
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Fig. I .  Scherne,for the hysteresis of acetylcholine ( A )  binding to the T. 
californica nicotinic acetylcholine receptor (nAcChR). [Reproduced 
from Neumann et al. (1988).] Bimolecular binding steps are aligned 
horizontally, whereas vertical steps are the slow structural iso- 
merizations. R, is the low-affinity form of the receptor with 
El !z 100 pM; Rh is the high-affinity conformer with Kh !z 0.1 pM and 
Rvh is the very high-affinity conformer with Kvh 5 5 (f 2) nM. The 
Rh . R, hybrid is a branch point from where Rvh . RI may form as 
dead-end product when pulses of A are applied giving rise to non- 
equilibrium states. The preferred direction of the isomerization 
equilibria is indicated by the thicker arrows. The long upper arrow 
indicates the channel activation pathway. At high [A] (> 10 pM), 
the low-affinity conformer R, is the major binding species which is 
responsible for channel opening. With prolonged exposure to AcCh, 
R, the receptor, is finally transformed into the high-affinity 
conformers, Rh and Rvh. At low [A] (< 10 pM), the Rh conformer is 
the predominant binding partner for AcCh and is on the direct route 
to the final complex A . Rvh. 'Single-pulse mode addition' of A favours 
formation of the hybrid binding state A .  R,, . RI which is a kind of 
dead-end state and can only be reversed when [A] becomes 1 1M. 
'Dialysis mode addition', i.e. equilibrium binding, ultimately leads to 
the dimeric A Rvh . A .  Rvh conformer complexes (see Fig. 6 and 
text). For further information Neumann et al. (1988) should be con- 
sulted 
activities is tightly coupled to AcCh binding, it is very likely 
that the AcCh binding hysteresis leads to a hysteresis of the 
receptor-mediated PtdIns phosphorylation - dephosphoryla- 
tion (see Carpenter and Cantley, 1990). Consequently, an event 
on the cell surface, such as hysteretic AcCh binding to the 
nAcCh receptor, i.e. with memory of the encounter, can be 
transduced across the membrane to the PtdIns pathway which, 
as a consequence, gains hysteretic properties and thus molec- 
ular memory. In summary (Fig. 7), AcCh binding is not only 
responsible for the hysteretic behaviour of the channel de- 
sensitization in the classical synaptic transmission, but may 
also cause a hysteretic modulation of the PtdIns pathway. 
Various subtypes of the nAcChR appear to differ in their 
channel functions in response to agonists and antagonists, 
but information is not yet available to what extent hysteretic 
transmitter binding and its consequences for desensitization 
differ among these isoforms. 
Returning to G-coupled hormone receptors, it is of course 
tempting to speculate that the high- and low-affinity states 
described by Lefkowitz and his coworkers (Stiles et al., 1984) 
for the /I-adrenoceptor are indicative of metastable con- 
formers. However, this cannot be decided on the basis of 
differences in affinity alone because different affinity states 
are necessary but insufficient criteria for metastability and 
hysteresis. But it would certainly be interesting to learn 
whether other transmitter and hormone receptors have hyster- 
etic properties like the Torpedo AcChR. 
Along the same line, it must be admitted that, based on 
presently available information and considering the bewilder- 
ing variety of post-translational epigenetic modifications of 
the /3-adrenoceptor, the G-proteins and adenylate cyclase, it 
is difficult to assign a clear and unequivocal functional or 
structural role to each of these structural changes (see Fig. 5). 
The modifications of protein components of signal trans- 
mission chains include, besides familiar modifications, such 
as glycosylation, phosphorylation, ADP-ribosylation, also 
myristoylation, isoprenylation and carboxymethylation (see 
Yamane et al., 1990; Fung et al., 1990; James and Olson, 
1990; Jones et al., 1990; Maltese and Robishaw, 1990; Mumby 
et al., 1990a, b). Special attention was given to the role of 
phosphorylation of the P-adrenoceptor in homologous desen- 
sitization (Hausdorff et al., 1990a). However, an inclusion of 
post-translational modifications in a discussion of structural 
and functional heterogeneity of receptors and G-proteins, 
even in a cursory manner, would go far beyond the scope of 
this review. 
The conformational transition due to the interaction of 
agonist with receptor is responsible for the formation of the 
active GTP-binding form of the G-protein. The activated re- 
ceptor acts as exchanger (Allende, 1988), promoting the dis- 
charge of GDP from the G-protein and the binding of GTP. 
But once the active GTP-binding form has been produced, 
the hormone-receptor complex is no longer required because 
the next step, namely the activation (or inhibition) of the 
target, is solely a matter to be decided by the target and its 
complementary activated G-protein (for a review see Pfeuffer 
and Helmreich, 1988; Birnbaumer et al., 1990). Thus, each 
G-protein-linked receptor must have domains to which the 
coupling partners can bind. Structural heterogeneity of the 
receptor is therefore only one side of the coin. In order to 
complete the picture, receptor heterogeneity must be discussed 
in conjunction with the structural properties of the coupling 
partners, the G-proteins. 
Structural properties of G-proteins 
The structural diversity is equally impressive in the case of 
G-proteins. GTP-binding proteins participating in hormonal 
signal transfer are heterotrimers with the structure a (Mr 
39000-46000), P (Mr 35000-36000 and 37000) and y (Mr 
8000- 10000). Only the a-subunits bind and hydrolyze GTP 
to GDP and Pi and are ADP-ribosylated by cholera toxin (G, 
and G,) or by pertussis toxin (Gt, Go, Gi). The more 
hydrophilic a-subunits of Go, Gi, G, and G, but not of G, are 
also N-myristoylated (Jones et al., 1990; Mumbyet al., 1990a). 
Thanks to recombinant DNA technology, nine genes and 
15 G a-subunits, which are products of these genes, have been 
identified so far (Harris et al., 1985; Bray et al., 1986; Itoh 
et al., 1986; Mattera et al., 1986; Nukada et al., 1986a, b; 
Robishaw et al., 1986a, b; Sullivan et al., 1986; Jones and 
Reed, 1987). But, this list is far from complete and additional 
subunits are being discovered continually. Four different a- 
subunits of G, and two out of four different a-subunits of Go 
are formed by alternative splicing (Itoh et al., 1986; Jones and 
Reed, 1987; Kozasa et al., 1988; Bertrand et al., 1990). 
How this structural heterogeneity is related to functional 
diversity is not yet clear. For example, G, activates adenylate 
cyclase but also dihydropyridine-sensitive Ca2 + channels 
(Yatani et al., 1987b; Brown and Birnbaumer, 1988; Mattera 
8 
Table 1. Function of G-proteins in signal transduction 
For literature consult Bray et al. (1986); Nukada et al. (1986a, b); Robishaw et al. (1986a, b); Stryer (1986); Barbacid (1987); Gilman (1987); 
Hescheler et al. (1987); Jones and Reed (1987, 1989); Schultz and Rosenthal (1987); Yatani et al. (1987a, b, 1988); Brown and Birnbaumer 
(1988); Fong et at. (1988); Itoh et al. (1988); Kozasa et al. (1988); Lochrie and Simon (1988); Matsuoka et al. (1988); Nakajima et al. (1988); 
Pfeuffer and Helmreich (1988); VanDongen et al. (1988); Freissmuth et al. (1989); Gilman (1989); Graziano et al. (1989); Mattera et al. 
(1989); Bertrand et al. (1990); Birnbaurner et al. (1990); Inanobe et al. (1990); Pang and Sternweis (1990); Price et al. (1990); Shinjo et al. 
(1990). See references in the text, especially for ras proteins. Please consult the text for further examples 
G-protein Effect Target Examples for horrnone/receptor 
-~ 
stimulation 
stimulation 
inhibition 
stimulation 
stirnulation (?) 
closing 
stimulation 
stimulation 
stimulation 
stimulation 
stimulation 
? 
? 
? 
adenylate cyclase 
CaZ + channels 
adenylate cyclase 
Ca" channel 
K' channel 
Ca2+ channel 
K +  channel 
cGMP phosphodiesterase 
adenylate cyclase 
phospholipase C 
phospholipase Az 
? 
? 
phospholipase C (?) 
Pl-, a,-adrenoceptors 
glucagon and others 
Dl -adrenoceptor 
orz-adrenoceptor 
angiotensin I1 
y-aminobutyrate 
or,-adrenoceptor 
bradykinin 
y-aminobut yrate 
neuropeptide Y 
rhodopsin 
olfactory receptors? 
al-adrenoceptors 
GI ,-adrenoceptors 
? 
growth factors (?) 
et al., 1989) and a pertussis-toxin-sensitive Gk from human 
red blood cells activates a K +  channel (see Table 1). Bourne 
and his colleagues have found a mutated G,, with a deleted 
Arg201 in tumours of the hypophysis with an accelerated 
rate of production of growth hormone and increased cellular 
cAMP levels (Landis et al., 1989). The same amino acid side 
chain is ADP-ribosylated in normal G,, by cholera toxin. 
Accordingly, the GTPase of this mutant G,, was blocked 
like that in normal ADP-ribosylated G,,, which explains the 
adenylate cyclase activation and the elevated cAMP levels. 
There are also two isoforms of the retinal G-protein, trans- 
ducin, G,, which link rhodopsin to the cGMP-specific 
phosphodiesterase. These isoforms are apparently expressed 
exclusively in retinal rods and cones, respectively (Lochrie et 
al., 1985; Medynski et al., 1985; Tanabe et al., 1985; 
Yatsunami and Khorana, 1985; Lerea et al., 1986). 
Gi was originally thought to be involved primarily in 
adenylate cyclase inhibition by inhibitory receptors, such as 
a,-adrenoceptors. Up to now, at least three different ai-sub- 
units are known (Itoh et al., 1986,1988; Nukada et al., 1986 b; 
Sullivan et al., 1986; Bray et al., 1987). They were named ai- 
l ,  xi-2, a,-3, on the basis of the order in which they were cloned 
(cf. Suki et al., 1987). They seem to be involved, as exemplified 
by the &-subunit of Gi-3, Gk, which opens atrial K+-channels 
(cf. Codina et al., 1987) in a variety of separate functions 
which are lumped together as pertussis-toxin-sensitive events 
(Schultz and Rosenthal, 1987; VanDongen et al., 1988; Yatani 
et al., 1988a). Some of these effects, for example regulation 
of cation channels, might turn out to be biologically as im- 
portant or more important as adenylate cyclase inhibition. 
One of the more abundant G-proteins is Go which is mainly 
found in brain where it amounts to 1% of all membrane 
proteins. There are at least four different Go,-subunits (Ina- 
nobe et al., 1990). Go, like Gi, can be linked to muscarinic 
acetylcholine receptors, a2-adrenoceptors, to rhodopsin and 
also to B1-adrenoceptors (see Kurstjens et al., 1991). The 
pertussis-toxin-sensitive events in which Go is involved are, 
like those in the case of Gi, not yet fully understood. Thus, Gi 
and Go have been assumed to play a role in the regulation of 
K and neuronal Ca2 + channels and in the coupling of the 
latter to the neuropeptide Y receptor and of the Na+-H+ 
antiporter (Hescheler et al., 1987; Yatani et al., 1987a, b; 
Ewald et al., 1988). An involvement of a pertussis-toxin-sensi- 
tive G-protein in the activation of phospholipase C, which 
leads to the formation of inositol trisphosphate and to the 
release of intracellular Ca2+, has been much discussed, but 
this G-protein has not yet been identified (Fain et al., 1988). 
Go has recently been shown to be a major component of 
the neuronal growth cone membrane and to interact with 
GAP-43, which is a growth-associated protein with M ,  43000 
(Strittmatter et al., 1990). GAP-43 stimulated GTP[yS]-bind- 
ing to Go. GAP-43 is unique among regulators of 
heterotrimeric G-proteins in that it is an intracellular protein 
and has an overall structure which is quite different from that 
of the G-protein-coupled receptors. 
Recently, a new G-protein, G, or G,, has been cloned 
(Fong et al., 1988; Matsuoka et al., 1988). It resembles Gig 
and Go, but with two notable differences: three amino acid 
residues in the first portion of the guanine-nucleotide-binding 
domain, which are strictly conserved in all other known a- 
subunits and which are assumed to be involved in the GTPase 
activity, are different. This leads apparently to drastically 
altered kinetics for the GTPase reaction of G,, (cf. Gilman, 
1989). The other difference is the absence of the cysteine 
residue near the carboxyl terminus which is the site for per- 
tussis-toxin-catalyzed ADP-ribosylation. Hence, G, could be 
responsible for GTP-dependent but pertussis-toxin-insensitive 
events. In some cells receptor-mediated regulation of 
phospholipase C activity might be such a pathway. G, might 
also have a function in the regulation of ion channels. For 
example, substance P is known to inhibit an outward rectifying 
potassium current in cultured brain neurons in a pertussis- 
toxin-insensitive but GTP-dependent fashion (Nakajima et 
al., 1988). G, might participate in this pathway. 
Other new G-proteins which are not ADP-ribosylated by 
pertussis toxin have come to light recently (Pang and 
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Sternweis, 1990). Moreover, olfactory neuron-specific G-pro- 
teins have been cloned (Jones and Reed, 1989). The latter 
have apparently a function in odorant signal transduction, 
although the odorant receptors have not yet been identified. 
Structurally similar G-proteins were also found in Drosophila 
(Provost et al., 1988), in yeast (Dietzel and Kurjan, 1987; 
Nakafuku et al., 1987, 1988) and in Dictyostelium (Pupillo et 
al., 1989) where they participate in regulation of adenylate 
cyclase activity and are involved in the function of mating 
factors in yeast. 
Other genes encode closely related but distinct B-subunits: 
the b-subunit of transducin is a protein with M ,  36000 
(Amatruda et a]., 1988), whereas the other G-proteins contain 
a doublet made up from a fl,-protein with M ,  36000 and a 
f12-protein with M ,  35000 (Sugimoto et al., 1985; Evans et al., 
1987; Fong et al., 1987; Gao et al., 1987). Recently a third 
( f 1 3 )  form of the /?-subunit was detected by screening bovine 
and human retina cDNA libraries. The encoded peptide with 
M ,  37000 is 83% identical with the fll form and 81% identical 
with the / j 2  form (Levine et al., 1990). 
A great variability of the y-subunits is now also becoming 
apparent: cDNAs encoding four structurally distinct y-sub- 
units have been identified. But the differences in the mobilities 
of y-subunits of several G-proteins (Gautam et al., 1990) and 
the isolation of proteolytic fragments from bovine brain G- 
proteins with amino acid sequences that are distinct from but 
similar to y-subunits suggest that unidentified members of 
the y-subunit family still exist (Gautam et al., 1989, 1990; 
Robishaw et al., 1989). 
Gautam et al. (1990) have recently probed the heterogen- 
eity of y-subunits from different tissues by cDNA synthesis 
using the polymerase chain reaction and immunoblot analysis 
using antibodies against synthetic peptides. Based on the pat- 
tern of tissue-specific expression, y-subunits were divided into 
three classes: y 2  which is ubiquitous; y3  which is tissue-specific 
and y1 which is cell-type-specific. There is evidence to support 
this notion because transducin from rod outer segments of the 
bovine eye, which has only one form of the fl-subunit (pl) 
(Amatruda et al., 1988), also has only one form of the y- 
subunit (yl) (Gautam et al., 1990). Thus the y-subunit of 
transducin and that of the G-proteins in brain which have 
been cloned and of which there are at least two types, are 
different. Moreover, the y-subunits associated with G,, Gi 
and Go from bovine brain also appear to be distinct species 
(Robishaw et al., 1989). 
A function for (fl)y-subunits in anchoring a-subunits to 
the membrane (Sternweis, 1986) is supported by the recent 
finding that the y-subunit of brain G-proteins is carboxy- 
methylated or isoprenylated at a C-terminal cysteine (Fung et 
al., 1990; Maltese and Robishaw, 1990; Mumbyet al., 1990b). 
As important might be a function of (&subunits in anchor- 
ing a-subunits to the receptor (Kurstjens et al., 1991). Based 
on the assumption that by-subunits are anchoring a-subunits 
to receptors, one might speculate that the diversity of y- (and 
/I-) subunits is partly responsible for enlarging the repertoire 
for interactions of a-subunits with receptors (Fig. 1 A and C; 
see also Gautam et al., 1990). But up to now there is no 
information available regarding the specificity of binding of 
/$subunits to receptors. 
Bourne et al. (1990) in a recent review have stated the 
prevailing notion, namely ‘that fly-subunits are believed to 
be involved in binding of a-subunits to the receptor and in 
increasing Kd for GDP but that they are not thought to have 
a direct role in discriminating between different receptor sub- 
types’. The latter is the crucial point because if the @)?-sub- 
unit, apart from the a-subunit, could also determine the speci- 
ficity of interaction of G-proteins with the receptor, this could 
be a device to link many more receptors, of which more than 
a hundred may exist, to G-protein-coupled signal transmission 
pathways. This suggestion has lately received some support 
from experiments with preparations of sealed unilamellar lipid 
vesicles which can be separated according to their size and 
density by sucrose gradient centrifugation. When separate a,- 
subunits were reconstituted with the fll-adrenoceptor some of 
them were recovered in the heavier vesicle fraction containing 
the receptor. But much more a, was bound in the presence of 
fly-subunits suggesting a cooperative anchoring function of 
receptor-bound by-subunits for a-subunits (Kurstjens et al., 
1991). 
One must be aware that these are qualitative data. Unfor- 
tunately, it has not yet been possible to assess the individual 
contributions of p- and y-subunits to the interaction with a- 
subunits of G, and to the interactions of the latter with recep- 
tors, because the p- and y-polypeptides can only be separated 
under denaturing conditions and separate (native) a,-subunits 
are not yet available (cf. Graziano et al., 1989). This will 
eventually be overcome by producing functional separate a-, 
fl-  and y-subunits with the aid of suitable gene expression 
systems. 
Therefore, whereas in the past the role of a-subunits was 
in the center of attention, it is now the role of the j- and y- 
subunits. They are interchangeable among the a-subunits of 
the nonretinal G-proteins, G,, Gi, Go, but G,, can discriminate 
between transducin fly, and the fly complex resolved from the 
nonretinal G-proteins of the brain (Hekman et al., 1987; Casey 
et al., 1989). However, quantitative information is lacking. 
Moreover, the fly-complex alone attaches to the receptor (Im 
et al., 1988; Kurstjens et al., 1991) and appears to be part of 
the recognition site for G-protein - a-subunits. by-Subunits 
also contribute in a concentration-dependent manner both 
to the hormonal activation and to the deactivation of G,, 
(Hekman et al., 1987). 
Whether &-subunits can interact directly or indirectly 
with target enzymes, such as adenylate cyclase and other effec- 
tors, in a functionally relevant manner remains open (Katada 
et al., 1986; Marbach et al., 1990). In this context it may be 
mentioned briefly that a controversy concerning the role of a- 
or py-subunits of Gi-3 (or Gk) in the regulation of muscarinic 
acetylcholine receptor-gated K + channels has received much 
attention. Whereas Logothetis et al. (1987, 1988) have report- 
ed that fly-subunits from brain and human placenta stimulate 
K + channels in guinea-pig atrial cells, Birnbaumer and 
coworkers (for more information see Brown and Birnbaumer, 
1988; Birnbaumer et al., 1990) have consistently observed 
that Gi,-subunits stimulate K + channels. The possibilities that 
these discrepancies are due to experimental variations in re- 
agents and detergents or are a consequence of the heterogen- 
eity of the preparations used has not yet been excluded. f l y -  
Subunits have also been implicated in the activation of cardiac 
phospholipase A2 (Axelrod et al., 1988) and it was speculated 
that the release of arachidonic acid as a consequence of the 
activation, is indirectly responsible for the activation of the 
K+-channels (Kim et al., 1989). 
A special case among GTP-binding proteins is the large 
and still expanding family of small GTP-binding proteins. 
Some 30 mammalian proteins of this type and several different 
subfamilies have by now been identified. Members of this 
family are composed of a single GTP-binding (a)-subunit with 
M ,  ranging between z 20000- 30000. They are either 
isoprenylated or palmitoylated or both (James and Olson, 
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1990). Usually, the small GTP-binding proteins do not serve 
as substrates for ADP-ribosylation by bacterial toxins, nor do 
they form heterotrimers with By-subunits. There are exceptions 
in the case of the rho proteins (Yamamoto el al., 1988) and 
the closely related rac proteins which are substrates for the C3 
exoenzyme of Clostridium botulinum (Aktories et al., 1987; 
Braun et al., 1989; Kikuchi et al., 1988). The modification 
results in a collapse of actin filaments, suggesting that rho 
proteins have a function in the cytoskeletal assembly of a cell 
(Rubin et al., 1988; Chardin et al., 1989). Wieland et al. (1990) 
have recently reported that rhoA is a target for rhodopsin and 
that ADP-ribosylation by C3 is inhibited by light. 
The function of the small G-proteins is understood in only 
a few cases: among these are the cytosolic ADP-ribosylation 
factor (ARF) which binds but does not hydrolyze GTP and 
which supports ADP-ribosylation by cholera toxin (Kahn and 
Gilman, 1986). This factor is apparently identical with the 
ARF gene product (Stearns et al., 1990) and with two other 
small-M, GTP-binding proteins in yeast which are products 
of the YPTI and SEC4 genes in Saccharornyces cerevisiae and 
which seem to be involved in the function of mating factors 
(Gallwitz et al., 1983; Salminen and Novick, 1987). The YPTI 
and SEC4 gene products and other GTP-binding proteins in 
yeast, e.g. products of the SARI  and ARF genes and the rab 
and arf families of GTP-binding proteins in mammalian cells 
may have important roles in vectorial membrane traffic, in 
vesicular transport, exocytosis and membrane fusion and in 
the function of the Golgi (Melancon et al., 1987; Nakano and 
Muramatsu, 1989; Walworth et al., 1989; Chavrier et al., 
1990; Stearns et al., 1990). In yeast a GTP-binding protein 
with M ,  21 000 is believed to be involved in endoplasmic 
reticulum Golgi protein transport (Nakano and Muramatsu, 
1989; for reviews see Balch, 1990; Burgoyne, 1990; Gomperts, 
1990; Rothman and Orci, 1990). An attractive candidate for 
such a role in mammalian cells is a small G-protein, named 
rab 3, which is only found in synaptic vesicles in neurons and 
in vesicles of endocrine cells: rab 3 binds tightly to membranes 
and has only 30% sequence similarity with oncogenic ras 
proteins (Fischer v. Mollard et al., 1990). 
The ras proteins are the most prominent members of this 
group. They are the products of the ras proto-oncogenes; 
one ras protein, H-ras p21, was crystallized and its three- 
dimensional structure resolved, first to about 0.25-nm and 
subsequently to 0.135-nm resolution (Pai et al., 1989, 1990). 
The ras proto-oncogene family codes for several small guan- 
ine-nucleotide-binding proteins with low intrinsic GTPase ac- 
tivities (for reviews see Barbacid, 1987; Burgoyne, 1989). Mu- 
tations inhibiting this activity produce a transforming protein, 
which suggests that ras proteins may play an important role in 
the control of cell proliferation, although their role in growth- 
factor-receptor-regulated signal transmission has remained 
elusive. Recently, an inhibition of coupling of muscarinic re- 
ceptors to atrial K+-channels by ras p21 and GTPase- 
activating protein, GAP, was reported (Yatani et al., 1990). 
In the case of the large trimeric @y-G-proteins in mam- 
mals, it is the hormone-activated receptor that functions as 
exchange factor, which promotes replacement of GDP by 
GTP. In Sacch. cerevisiae the product of the CDC25 gene 
appears to have a similar function (cf. Fischer v. Mollard et 
al., 1990). Another exchange factor increasing the off rate of 
GDP from the eukaryotic initiation factor, eIF2, is GEF 
(GDP-exchange factor), a large cytosolic multisubunit com- 
plex. The off rates for guanine nucleotides in the case of eIF2 
are as slow as those of ras; it makes sense therefore that 
cytosolic factors exist that enhance hydrolysis of GTP by ras 
(Vogel et al., 1988; for reviews see McCormick, 1989; Hall, 
1990). Such a GAP-like protein was isolated from brain 
cytosol; it effectively catalyzed the release of bound GDP 
from ras in the presence of Mg2+. This protein was different 
from GAP and GEF (cf. Wolfman and Macara, 1990). Similar 
proteins seem to exist in yeast: these are the GAP homologues 
encoded by the IRA1 and IRA2 genes (Ballester et al., 1989; 
Tanaka et al., 1989). Therefore, there may be as many GAP, 
GTPase-activating proteins, as GTP-binding proteins. 
Structural properties of adenylate cyclase 
and other target enzymes 
There are at least three, and most likely four, kinds of 
adenylate cyclase in mammalian cells: all are activated by G- 
proteins and one form is additionally regulated by calmodulin 
(Mollner and Pfeuffer, 1988). Ca2 +-calmodulin sensitivity 
may be a special property of neural adenylate cyclases (Eliot 
et al., 1989). An immunologically different calmodulin-insen- 
sitive adenylate cyclase has been found in the olfactory 
epithelia of the rat (Pfeuffer et al., 1989). And recently, a new 
olfactory adenylate cyclase, termed type 111, was cloned and 
expressed (Bakalyar and Reed, 1990). 
It will be interesting to see how many isoforms of adenylate 
cyclase are expressed and whether differently regulated 
adenylate cyclases are found. A calmodulin-sensitive adenyl- 
ate cyclase from bovine brain was cloned and sequenced (Kru- 
pinski et al., 1989). It was already known that adenylate 
cyclase is a glycoprotein like the adrenoceptor (Pfeuffer et al., 
1985). Now it became apparent that adenylate cyclase, like 
the adrenoceptor and rhodopsin, has a large number (12) of 
hydrophobic transmembrane cr-helical segments. 
Another remarkable feature is the similarity of the 
adenylate cyclase structure and that of Ca2 + and K +  channels, 
and the so-called P-glycoprotein which is the product of the 
multidrug resistance gene (Gottesman and Pastan, 1988). The 
P-protein is responsible for the cellular export and the elimi- 
nation of a number of chemical compounds and drugs. Ac- 
cordingly, Gilman and colleagues (Krupinski et al., 1989), who 
have unravelled the structure, have suggested that mammalian 
adenylate cyclase may not only form but also export cAMP 
into the extracellular medium. A pathway which produces 
and secretes cAMP must exist in Dictyostelium discoideum 
(Devreotes, 1989) where cAMP actually serves as an extra- 
cellular signal for chemotaxis, cell adhesion and aggregation 
(cf. Klein et al., 1988). 
A membrane-bound form of guanylate cyclase was like- 
wise cloned and sequenced recently (Chinkers et al., 1989; for 
a review see Schulz et al., 1989). The guanylate cyclase belongs 
to a novel receptor family in which the binding of the agonist 
or hormone, for example of the atrial natriuretic peptide, 
initiates activation in one and the same peptide chain without 
involvement of other transducing elements. Guanylate cyclase 
is a double-headed receptor enzyme where the catalytic do- 
main, which forms and releases cGMP, is oriented towards 
the cytosol. 
We are aware that the list of target enzymes of G-protein- 
dependent signal transmission chains is incomplete. For ex- 
ample, there is evidence of heterogeneity also in the case of 
phospholipase C. In fact, several species of phospholipase C 
have been purified and three different cDNAs were cloned 
(Katan et al., 1988; Suh et al., 1988). There are also several 
forms of cGMP phosphodiesterase linked to transducin 
(Hurwitz et al., 1984, 1985; Stryer, 1986; Beavo, 1988). There 
is little sequence similarity apparent between G-protein- 
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coupled adenylate cyclase, phospholipase C and cGMP 
phosphodiesterase. Thus, based on primary sequence, a com- 
mon consensus domain in these target enzymes for G-protein 
interactions cannot be made out. This points to the need for 
more information on a higher structural level. 
Implications of structural heterogeneity of receptors 
and G-proteins for multiple responses 
AS is shown in Fig. 1 A, originally it was believed that a 
variety of different receptors could be channeled via a com- 
mon G-protein to their target or effector, for example 
adenylate cyclase. Families of stimulatory and inhibitory re- 
ceptors were thought to regulate exclusively adenylate cyclase 
activity by means of stimulatory (G,) or inhibitory (Gi) pro- 
teins. But it has become evident that G-proteins such as Gi or 
G, have multiple functions and can interact with other targets 
besides adenylate cyclase, for example with cation channels 
(see Table 1 j. 
The functional diversity raises the question of whether or 
not, for each of these separate functions, a separate, structur- 
ally distinct G-protein is required (see Fig. 1, B and C). There 
are many examples known of two or more distinct separate 
functions of one given hormone, even in one line of cells. 
For example, thrombin receptors in human platelets stimulate 
phospholipase C activity (Watson et al., 1984j, but also inhibit 
adenylate cyclase (Jakobs et al., 1985; Katada et al., 1985). 
Other examples are vasopressin and angiotensin I1 receptors 
in liver (Pobiner et al., 1985; Uhing et al., 1986) and thyroid- 
releasing-hormone receptors in GH4C cells (Straub and 
Gershengorn, 1986). Moreover, it has been indicated that aZ- 
adrenergic receptors and Mz-muscarinic AcCh receptors may 
have more than one function (Yatani et al., 1987b, c). The 
same applies to neuropeptide Y (Ewald et al., 1988) and opioid 
receptors (Hescheler et al., 1987). Another example is that 
a,-adrenergic stimulation activates independently both 
phospholipase C and phospholipase A2 (Burch et al., 1986; 
for other examples see Knecht et a)., 1987 and Cotecchia et 
al., 1990). 
Since single cells can express multiple subtypes of the same 
receptor, as demonstrated in glioma cells which express both 
fil- and P,-adrenergic receptors (Homburger et al., 1981), 
these multiple actions of a given hormone were ascribed to 
receptor heterogeneity. In some cases structurally and func- 
tionally different receptors were distinguished on the basis of 
high and low affinity for one given hormone. For example, in 
the case of glucagon receptors on hepatocytes, high-affinity/ 
low-capacity receptors were believed to be associated with the 
formation of inositol trisphosphate and rise in intracellular 
Ca2', whereas those of lower affinity but higher capacity were 
thought to be responsible for adenylate cyclase activation and 
a rise in CAMP (Wakelam et a]., 1986). 
A similar situation was observed in platelets in the case of 
prostaglandin El receptors where the lower-affinity receptor 
was again associated with adenylate cyclase, while the function 
of the higher-affinity receptor remained unclear (Mruk et al., 
1982). On the other hand, glucagon and prostaglandin El  
receptors on MDCK cells are activated by their respective 
agonists, apparently in about the same range of concen- 
trations, but each appears to be responsible for a concomitant 
rise in intracellular Ca2+ and CAMP, suggesting that a single 
receptor may activate more than one G-protein (Kurstjens 
et al. 1990). This was first demonstrated in reconstitution 
experiments where it was shown that rhodopsin stimulated 
not only GTP hydrolysis by transducin, but also by a mixture 
of human erythrocyte Gi-2 and Gi-3 proteins (Cerione et al., 
1985). Later, it was shown that a P1-adrenoceptor interacts 
not only with G,, its true partner, but also with Go (Kurstjens 
et al., 1991). 
The most convincing e\!idence that a single receptor may 
indeed interact with more than one type of G-protein comes 
from experiments with a cardiac Mz-muscarinic acetylcholine 
receptor clone with which cells were transfected. Activation 
of the M2-receptor in the transfected cells by acetylcholine 
resulted in inhibition of adenylate cyclase, i.e. activation of Gi  
and likewise in stimulation of phospholipase C by another G- 
protein (named GP) (Ashkenazi et al., 1987). Therefore, it is 
quite Iikely that one receptor can couple to more than one G- 
protein and regulate more than one effector function. Thus 
the capability of one G-protein-linked hormone receptor to 
activate two or more separate signal transmission pathways, 
as for example the neuropeptide Y1 receptor (Aakerlund et 
al., 1990), could therefore be interpreted as a functional corre- 
late to the structural diversity of transducing elements, on 
the one hand, and as reflecting structural heterogeneity of 
receptors, on the other. 
While the evidence is impressive that one receptor can 
interact with more than one G-protein, it is still a matter of 
speculation whether one effector might interact with more 
than one G-protein. This is shown in Fig. 1 C. Considering 
the different structural and functional properties of well 
characterized targets, such as cGMP phosphodiesterase, 
phospholipase C and adenylate cyclase, it would seem less 
likely that one G-protein can interact productively with more 
than one effector system. But this problem remains open until 
we know how many isoforms of effectors exist and how differ- 
ent they are structurally. This situation is depicted in Fig. 1 B. 
Notwithstanding the examples cited above, the infor- 
mation presently available does not allow us to distinguish 
sharply between these possibilities or exclude one or the other. 
For example, i t  is still a matter of speculation whether sub- 
types of one receptor species with different affinities and B,,, 
values for ligands are responsible for different functions at the 
cellular level, or whether functional pleiotropy is due to the 
fact that more than one G-protein couples to each receptor. 
Both situations may conceivably exist and could contribute 
to functional diversity and accommodate the ever widening 
spectrum of cellular processes in which G-proteins play a 
crucial role (see Table 1). In order to clarify multiple recep- 
tor - effector - G-protein interactions, it will be necessary to 
characterize each cell type with respect to structure and func- 
tion of receptors and G-proteins. Moreover, since it is to be 
expected that differences in interaction parameters of 
components of a signal transmission chain are quite subtle, 
more precise and quantitative assays will be needed. 
Outlook 
The purpose of this review is to make clear how profoundly 
the proliferation of structural information on receptors, G- 
proteins and targets revealing great heterogeneity has influ- 
enced our thinking on hormone action, thinking which was 
previously dominated primarily by the pharmacologists' in- 
terpretation of selectivity and specificity of hormone binding 
and its consequences. The structural heterogeneity of recep- 
tors and G-proteins brought to light by the recombinant DNA 
technology points to a high level of complexity. Perhaps this 
complexity might have been anticipated from a consideration 
of the pleiotropic effects of hormones, but it creates new 
problems not appreciated until now and points to the need 
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for a different kind of information in order to tackle the 
problems of structural heterogeneity and ambiguity of coup- 
ling interactions in the course of receptor activation and ampli- 
fication of hormone action. 
At the cellular level, use can be made of mutant cells where 
one or the other component of a hormonal signal chain is 
mutated or deleted. Moreover, structurally defined and 
characterized isoforms can be expressed in heterologous cells 
and the functional consequences studied. The other approach 
aims at the molecular level: in order to detect multiple recep- 
tor - effector - G-protein interactions and test proteins 
engineered by site-directed mutagenesis, it will be necessary 
to use more precise and quantitative assays in order to define 
the limits within which partners can actually interact and 
recognize each other. Thus, these assays must allow us to 
distinguish subtly among several interacting partners on the 
basis of differences in affinities and kinetics. 
Use can be made of reconstituted proteoliposomes. Re- 
cently, fluorescence energy transfer was applied in a study of 
rhodopsin - G-protein interaction (Borochov-Neori and 
Montal, 1989). This is also being used in our laboratory (un- 
published results) for the study of interactions of G-protein 
subunits with the fl-adrenoceptor using liposomes reconsti- 
tuted with pure separate receptor and a- and py-subunits. This 
is only one among several experimental approaches which 
could be pursued. 
However, since all the important questions which need to 
be answered are centered around the structural comp- 
lementarity between G-proteins and their respective partners, 
receptors and targets, three-dimensional structures of the pro- 
teins interacting in signal transmission chains in membranes 
would provide the most convincing information. Without 
three-dimensional structures of receptors, G-proteins, target 
enzymes and channels, we will not be able to translate structur- 
al properties into functional characteristics. No detailed X- 
ray structures of membrane proteins, which are constituents 
of signal transduction pathways are yet available with the 
exception of ras p21 (Pai et al., 1989, 1990) whose role in 
signal transmission is, however, not clear. Only when structur- 
al information at the molecular level is available, as it is 
for hemoglobin and a few other allosterically regulated key 
enzymes of metabolism (for a review see Perutz, 1989), will 
the confusing and at present overwhelming complexity of 
possible interactions between participants in signal trans- 
mission pathways become interpretable. 
Just a few basic patterns of structure/function relation- 
ships might emerge and restore order. This hope is based on 
the assumption that G-proteins and their coupling partners, 
because of their physiological importance, are proteins with 
conserved functional domains. Accordingly, one might expect 
that some basic mechanisms for cooperative conformational 
transitions have emerged in the course of evolution which 
determine interactions between a-, p- and y-subunits on the 
one hand and between these subunits and a variety of receptors 
and effectors on the other. Once we understand these mechan- 
isms, it will be possible to construct a dense, versatile and 
responsive regulatory network for transmitter and hormone 
control of cell function on the basis of a few principles for 
structural transitions. 
The pioneering phase, in which classical biochemistry and 
recombinant cDNA technology brought us the isolation and 
characterization of G-proteins, receptors, channels and target 
enzymes, is coming to an end. The biochemical information 
must now be supplemented by three-dimensional structural 
analyses of these membrane proteins. A beginning has already 
been made in the case of a complex membraneous multicom- 
ponent system, the photosynthetic reaction center in Rhodo- 
pseudomonas viridis (Deisenhofer and Michel, 1989). The 
X-ray crystallographers are now called upon to meet this 
challenge. 
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